Abbott (ABT.US) saw a surge in demand for medical equipment in Q2, boosting performance, but the stock price plummeted due to lower-than-expected guidance.

According to the Securities Times APP, due to strong demand for medical devices such as continuous glucose monitoring systems, the performance reported by Abbott (ABT.US) on Thursday exceeded Wall Street expectations. However, due to performance guidance being below market expectations, the company's stock price fell before the market opened.